H.C. Wainwright raised the firm’s price target on Oric Pharmaceuticals to $21 from $15 and keeps a Buy rating on the shares following the Q4 report. The initial Phase 1b data for ORIC-944, which is being studied in metastatic prostate cancer, is a catalyst in mid-2024, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ORIC:
- Oric Pharmaceuticals price target raised to $17 from $14 at Oppenheimer
- Oric Pharmaceuticals price target lowered to $25 from $27 at Baird
- Oric Pharmaceuticals files automatic mixed securities shelf
- ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
- Oric Pharmaceuticals reports Q4 EPS (49c), consensus (49c)
